KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Payables (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Payables for 11 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Payables fell 24.28% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Dec 2025, down 24.28% year-over-year, with the annual reading at $11.1 million for FY2025, 24.28% down from the prior year.
  • Payables hit $11.1 million in Q4 2025 for CRISPR Therapeutics AG, down from $11.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $45.2 million in Q1 2023 to a low of $9.5 million in Q2 2024.
  • Historically, Payables has averaged $20.0 million across 5 years, with a median of $15.2 million in 2021.
  • Biggest five-year swings in Payables: skyrocketed 215.87% in 2022 and later crashed 65.74% in 2024.
  • Year by year, Payables stood at $14.8 million in 2021, then soared by 85.12% to $27.4 million in 2022, then soared by 39.08% to $38.1 million in 2023, then tumbled by 61.44% to $14.7 million in 2024, then decreased by 24.28% to $11.1 million in 2025.
  • Business Quant data shows Payables for CRSP at $11.1 million in Q4 2025, $11.8 million in Q3 2025, and $9.8 million in Q2 2025.